Targeting FGFR Mutations in Metastatic Urothelial Cancer

Drs Arlene O. Siefker-Radtke and Scott T. Tagawa comment on opportunities for treating metastatic urothelial cancer with FGFR targeted therapies based on current trends in molecular testing and emerging therapies.

EP. 11: FGFR Inhibitors in Metastatic Urothelial Cancer and the Management of Ocular Toxicity

December 15th 2021

What oncologists need to know about the management of ocular toxicity for patients with metastatic urothelial cancer receiving FGFR-targeted therapy.

EP. 12: Mitigating FGFR Inhibitor TRAEs in Metastatic Urothelial Cancer

December 15th 2021

An overview of adverse events commonly associated with FGFR-targeted therapies such as erdafitinib.

EP. 13: Future Outlook on the Management of Metastatic Urothelial Cancer

December 15th 2021

Drs Arlene O. Siefker-Radtke and Scott T. Tagawa consider how the urology field will likely advance with more interest in genomic profiling in metastatic urothelial cancer and novel therapies in the pipeline.